Regeneron Pharmaceuticals announced that it will acquire Sanofi’s stake in the Regeneron- Sanofi collaboration on the cancer drug Libtayo (cemiplimab) for $900 million up front, 11 percent royalties on worldwide sales and other milestone payments.
Source: Drug Industry Daily